Greenwich LifeSciences, Inc. (GLSI) Financial Statements (2024 and earlier)

Company Profile

Business Address 3992 BLUEBONNET DR, BUILDING 14
STAFFORD, TX 77477
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,468,02627,204,26928,660,375
Cash and cash equivalents13,468,02627,204,26928,660,375
Total current assets:13,468,02627,204,26928,660,375
Noncurrent Assets
Intangible assets, net (including goodwill)9,00312,61516,227
Intangible assets, net (excluding goodwill)9,00312,61516,227
Total noncurrent assets:9,00312,61516,227
TOTAL ASSETS:13,477,02927,216,88428,676,602
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:220,845220,845710,971
Employee-related liabilities164,32759,367
Accrued liabilities42,060  
Other undisclosed accounts payable and accrued liabilities178,78556,518651,604
Due to related parties  275,154
Other undisclosed current liabilities42,060164,32759,367
Total current liabilities:262,905385,1721,045,492
Noncurrent Liabilities
Total liabilities:262,905385,1721,045,492
Equity
Equity, attributable to parent13,214,12426,831,71227,631,110
Common stock12,84813,14812,704
Additional paid in capital54,674,04260,466,09356,695,359
Accumulated deficit(41,472,766)(33,647,529)(29,076,953)
Total equity:13,214,12426,831,71227,631,110
TOTAL LIABILITIES AND EQUITY:13,477,02927,216,88428,676,602

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Operating expenses(8,040,254)(4,597,943)(1,863,794)
Operating loss:(8,040,254)(4,597,943)(1,863,794)
Nonoperating income
(Investment Income, Nonoperating)
215,01727,367832
Loss from continuing operations:(7,825,237)(4,570,576)(1,862,962)
Loss before gain (loss) on sale of properties:(4,570,576)(1,862,962)
Net loss available to common stockholders, diluted:(7,825,237)(4,570,576)(1,862,962)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Net loss:(7,825,237)(4,570,576)(1,862,962)
Comprehensive loss, net of tax, attributable to parent:(7,825,237)(4,570,576)(1,862,962)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: